Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Summa Cardiovascular Institute, Summa Health System, Akron, Ohio, USA.
Stem Cells Transl Med. 2018 Jan;7(1):115-124. doi: 10.1002/sctm.17-0172. Epub 2017 Nov 9.
Diabetes is a risk factor for worse outcomes following acute myocardial infarction (AMI). In this study, we tested the hypothesis that SDF-1:CXCR4 expression is compromised in post-AMI in diabetes, and that reversal of this defect can reverse the adverse effects of diabetes. Mesenchymal stem cells (MSC) isolated from green fluorescent protein (GFP) transgenic mice (control MSC) were induced to overexpress stromal cell-derived factor-1 (SDF-1). SDF-1 expression in control MSC and SDF-1-overexpressing MSC (SDF-1:MSC) were quantified using enzyme-linked immunosorbent assay (ELISA). AMI was induced on db/db and control mice. Mice were randomly selected to receive infusion of control MSC, SDF-1:MSC, or saline into the border zone after AMI. Serial echocardiography was used to assess cardiac function. SDF-1 and CXCR4 mRNA expression in the infarct zone of db/db mice and control mice were quantified. Compared to control mice, SDF-1 levels were decreased 82%, 91%, and 45% at baseline, 1 day and 3 days post-AMI in db/db mice, respectively. CXCR4 levels are increased 233% at baseline and 54% 5 days post-AMI in db/db mice. Administration of control MSC led to a significant improvement in ejection fraction (EF) in control mice but not in db/db mice 21 days after AMI. In contrast, administration of SDF-1:MSC produced a significant improvement in EF in both control mice and db/db mice 21 days after AMI. The SDF-1:CXCR4 axis is compromised in diabetes, which appears to augment the deleterious consequences of AMI. Over-express of SDF-1 expression in diabetes rescues cardiac function post AMI. Our results suggest that modulation of SDF-1 may improve post-AMI cardiac repair in diabetes. Stem Cells Translational Medicine 2018;7:115-124.
糖尿病是急性心肌梗死(AMI)后预后不良的一个危险因素。在本研究中,我们检验了这样一个假设,即在糖尿病中,基质细胞衍生因子-1(SDF-1):CXCR4 的表达在 AMI 后受到损害,而逆转这种缺陷可以逆转糖尿病的不良影响。从绿色荧光蛋白(GFP)转基因小鼠中分离间充质干细胞(MSC)(对照 MSC),诱导其过表达基质细胞衍生因子-1(SDF-1)。采用酶联免疫吸附试验(ELISA)定量检测对照 MSC 和 SDF-1 过表达 MSC(SDF-1:MSC)中的 SDF-1 表达。在 db/db 和对照小鼠中诱导 AMI。AMI 后,随机选择小鼠接受对照 MSC、SDF-1:MSC 或生理盐水输注到边界区。连续进行超声心动图检查以评估心功能。定量检测 db/db 小鼠和对照小鼠梗死区的 SDF-1 和 CXCR4 mRNA 表达。与对照小鼠相比,db/db 小鼠在基线、AMI 后 1 天和 3 天 SDF-1 水平分别降低 82%、91%和 45%,而 CXCR4 水平在基线时升高 233%,在 AMI 后 5 天升高 54%。AMI 后 21 天,给予对照 MSC 可显著改善对照小鼠的射血分数(EF),但对 db/db 小鼠无效。相比之下,AMI 后 21 天,给予 SDF-1:MSC 可显著改善对照小鼠和 db/db 小鼠的 EF。SDF-1:CXCR4 轴在糖尿病中受损,这似乎加剧了 AMI 的有害后果。糖尿病中 SDF-1 表达的过表达可挽救 AMI 后的心功能。我们的研究结果表明,调节 SDF-1 可能改善糖尿病患者 AMI 后的心脏修复。Stem Cells Translational Medicine 2018;7:115-124.